Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 10, 2023

BUY
$79.22 - $105.37 $666,636 - $886,688
8,415 Added 105.1%
16,422 $1.67 Million
Q1 2023

May 11, 2023

BUY
$30.85 - $93.17 $38,840 - $117,301
1,259 Added 18.66%
8,007 $727,000
Q4 2022

Feb 09, 2023

SELL
$22.15 - $42.11 $81,445 - $154,838
-3,677 Reduced 35.27%
6,748 $256,000
Q3 2022

Nov 10, 2022

SELL
$19.41 - $36.49 $28,513 - $53,603
-1,469 Reduced 12.35%
10,425 $262,000
Q2 2022

Aug 10, 2022

BUY
$20.71 - $36.5 $71,076 - $125,268
3,432 Added 40.56%
11,894 $361,000
Q1 2022

May 12, 2022

SELL
$24.12 - $39.6 $76,581 - $125,730
-3,175 Reduced 27.28%
8,462 $278,000
Q4 2021

Feb 10, 2022

SELL
$25.61 - $110.96 $397,185 - $1.72 Million
-15,509 Reduced 57.13%
11,637 $307,000
Q3 2021

Nov 10, 2021

BUY
$100.0 - $143.02 $2.71 Million - $3.88 Million
27,146 New
27,146 $2.73 Million

Others Institutions Holding RETA

About REATA PHARMACEUTICALS INC


  • Ticker RETA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 31,583,200
  • Description
  • Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney diseas...
More about RETA
Track This Portfolio

Track Citigroup Inc Portfolio

Follow Citigroup Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.